119838-37-8 Usage
Description
(R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate is a chiral chemical compound belonging to the class of imidazolidinones. It features a tert-butyl and a methyl group attached to the imidazolidinone ring, along with a phenyl group and a hydroxy group connected to the carbon atom. (R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate holds potential for various applications in pharmaceuticals, agrochemicals, and materials science, with its chiral nature also making it valuable for asymmetric synthesis and as a chiral ligand in catalytic reactions.
Uses
Used in Pharmaceutical Industry:
(R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate is used as a potential candidate for the development of new drugs due to its unique chemical structure and chiral nature. Its ability to be utilized in asymmetric synthesis and as a chiral ligand in catalytic reactions contributes to the creation of novel pharmaceutical compounds with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, (R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate may be employed as a building block for the synthesis of new agrochemicals, such as pesticides and herbicides, that can target specific pests or weeds while minimizing harm to the environment and non-target organisms.
Used in Materials Science:
(R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate can be used as a component in the development of advanced materials with unique properties. Its incorporation into polymers or other materials could lead to the creation of new materials with enhanced performance characteristics, such as improved strength, durability, or chemical resistance.
As a Chiral Ligand in Catalytic Reactions:
(R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate is used as a chiral ligand in catalytic reactions, enabling the selective synthesis of enantiomerically pure compounds. This application is particularly relevant in the pharmaceutical industry, where the development of single-enantiomer drugs with improved efficacy and reduced side effects is of high importance.
As a Building Block for Asymmetric Synthesis:
(R)-2-tert-butyl-3-Methyl-4-oxoiMidazolidin-1-iuM (R)-2-hydroxy-2-phenylacetate is also used as a building block in asymmetric synthesis, allowing for the creation of chiral molecules with specific configurations. This is crucial in various industries, including pharmaceuticals and agrochemicals, where the stereochemistry of a molecule can significantly impact its biological activity and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 119838-37-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,9,8,3 and 8 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 119838-37:
(8*1)+(7*1)+(6*9)+(5*8)+(4*3)+(3*8)+(2*3)+(1*7)=158
158 % 10 = 8
So 119838-37-8 is a valid CAS Registry Number.
119838-37-8Relevant articles and documents
RESOLUTION AND USE IN α-AMINO ACID SYNTHESIS OF IMIDAZOLIDINONE GLYCINE DERIVATIVES
Fitzi, Robert,Seebach, Dieter
, p. 5277 - 5292 (2007/10/02)
The imidazolidinones (rac.-1 and rac.-2) obtained from pivalaldehyde and glycine amides are resolved efficiently by crystallization of diastereomeric ammonium salts with chiral acids (mandelates and a gulonate respectively).The free bases are acylated under Schotten-Baumann conditions to give enantiomerically pure 1-Bz-, 1-BOC-, 1-Z- or 1-formyl-2-t-butyl-3-methyl- or -3-benzyl-4-imidazolidinones.Diastereoselective alkylation of the 3-methyl derivatives (BMI) with a variety of electrophiles (LDA/THF -70 to +25 degC) gives trans-disubstituted imidazolidinones exclusively (3-22).Some of these are hydrolyzed by a procedure employing excess acidic ion exchange resin to give enantiomerically pure (R)- or (S)-amino acids.The procedure is compared with other methods of generating chiral glycine enolates.
